Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD; 2020 Available from: http://goldcopd.org/. Accessed 325, 2020.
   Google Scholar
• FordES, CroftJB, ManninoDM, WheatonAG, ZhangX, GilesWH. COPD surveillance—United States, 1999–2011. Chest. 2013;144(1):284–305. doi:10.1378/chest.13-080923619732
   PubMed Web of Science ®Google Scholar
• JenkinsCR, ChapmanKR, DonohueJF, RocheN, TsiligianniI, HanMK. Improving the management of COPD in women. Chest. 2017;151(3):686–696. doi:10.1016/j.chest.2016.10.03127816445
   PubMed Web of Science ®Google Scholar
• StallbergB, JansonC, JohanssonG, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1):38–45. doi:10.4104/pcrj.2013.0010624346825
   PubMedGoogle Scholar
• American Lung Association. Taking her breath away. The rise of COPD in women; 2013 Available from: https://www.lung.org/assets/documents/research/rise-of-copd-in-women-full.pdf. Accessed 612, 2019.
   Google Scholar
• BrownDW, CroftJB, GreenlundKJ, GilesWH. Deaths from chronic obstructive pulmonary disease — United States, 2000–2005. MMWR. 2008;57:1229–1232.19008792
   PubMedGoogle Scholar
• MachadoMC, KrishnanJA, BuistSA, et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(5):524–529. doi:10.1164/rccm.200507-1057OC16778158
   PubMed Web of Science ®Google Scholar
• OharJ, FromerL, DonohueJF. Reconsidering sex-based stereotypes of COPD. Prim Care Respir J. 2011;20(4):370–378. doi:10.4104/pcrj.2011.0007021922124
   PubMedGoogle Scholar
• CelliB, VestboJ, JenkinsCR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011;183(3):317–322. doi:10.1164/rccm.201004-0665OC20813884
   PubMed Web of Science ®Google Scholar
• de TorresJP, CasanovaC, HernandezC, AbreuJ, Aguirre-JaimeA, CelliBR. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128(4):2012–2016. doi:10.1378/chest.128.4.201216236849
   PubMed Web of Science ®Google Scholar
• Di MarcoF, VergaM, ReggenteM, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100(10):1767–1774. doi:10.1016/j.rmed.2006.01.02616531031
   PubMed Web of Science ®Google Scholar
• MartinezFJ, CurtisJL, SciurbaF, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–252. doi:10.1164/rccm.200606-828OC17431226
   PubMed Web of Science ®Google Scholar
• NaberanK, AzpeitiaA, CantoniJ, MiravitllesM. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106(3):367–373. doi:10.1016/j.rmed.2011.09.01422018505
   PubMed Web of Science ®Google Scholar
• NiccoliniA, BarbagelataE, TagliabueE, ColomboD, MonacelliF, BraidoF. Gender differences in chronic obstructive pulmonary disease: a narrative review. Panminerva Med. 2018;60(4):192–199. doi:10.23736/S0031-0808.18.03463-829856178
   PubMed Web of Science ®Google Scholar
• RaghavanD, VarkeyA, BartterT. Chronic obstructive pulmonary disease: the impact of gender. Curr Opin Pulm Med. 2017;23(2):117–123. doi:10.1097/MCP.000000000000035327977622
   PubMed Web of Science ®Google Scholar
• GanWQ, ManSF, PostmaDS, CampP, SinDD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res. 2006;7(1):52. doi:10.1186/1465-9921-7-5216571126
   PubMed Web of Science ®Google Scholar
• WatsonL, VestboJ, PostmaDS, et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med. 2004;98(12):1207–1213. doi:10.1016/j.rmed.2004.05.00415588042
   PubMed Web of Science ®Google Scholar
• BeehKM, GlaabT, StowasserS, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013;14(1):116. doi:10.1186/1465-9921-14-11624168767
   PubMed Web of Science ®Google Scholar
• de TorresJP, CasanovaC, HernandezC, et al. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health Qual Life Outcomes. 2006;4(1):72. doi:10.1186/1477-7525-4-7217007639
   PubMed Web of Science ®Google Scholar
• DeMeoDL, RamagopalanS, KavatiA, et al. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. 2018;13:3021–3029. doi:10.2147/COPD.S16027030319250
   PubMed Web of Science ®Google Scholar
• SorheimIC, JohannessenA, GulsvikA, BakkePS, SilvermanEK, DeMeoDL. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax. 2010;65(6):480–485. doi:10.1136/thx.2009.12200220522842
   PubMed Web of Science ®Google Scholar
• SuhJJ, PettinatiHM, KampmanKM, O’BrienCP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463–468. doi:10.1080/1055049080240907419034737
   PubMed Web of Science ®Google Scholar
• AgustiA, CalverleyPM, CelliB, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-12220831787
   PubMed Web of Science ®Google Scholar
• BecklakeMR, KauffmannF. Gender differences in airway behaviour over the human life span. Thorax. 1999;54(12):1119–1138. doi:10.1136/thx.54.12.111910567633
   PubMed Web of Science ®Google Scholar
• HanMK, Arteaga-SolisE, BlenisJ, et al. Female sex and gender in lung/sleep health and disease. Increased understanding of basic biological, pathophysiological, and behavioral mechanisms leading to better health for female patients with lung disease. Am J Respir Crit Care Med. 2018;198(7):850–858. doi:10.1164/rccm.201801-0168WS29746147
   PubMed Web of Science ®Google Scholar
• HanMK, PostmaD, ManninoDM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. 2007;176(12):1179–1184. doi:10.1164/rccm.200704-553CC17673696
   PubMed Web of Science ®Google Scholar
• LiX, ObeidatM, ZhouG, et al. Responsiveness to ipratropium bromide in male and female patients with mild to moderate chronic obstructive pulmonary disease. EBioMedicine. 2017;19:139–145. doi:10.1016/j.ebiom.2017.04.02028461224
   PubMed Web of Science ®Google Scholar
• AbergJ, HasselgrenM, MontgomeryS, et al. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:961–969. doi:10.2147/COPD.S19331131123398
   PubMed Web of Science ®Google Scholar
• RinneST, ElwyAR, LiuCF, et al. Implementation of guideline-based therapy for chronic obstructive pulmonary disease: differences between men and women veterans. Chron Respir Dis. 2017;14(4):385–391. doi:10.1177/147997231770214128618875
   PubMed Web of Science ®Google Scholar
• TashkinD, CelliB, KestenS, LystigT, DecramerM. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010;104(10):1495–1504. doi:10.1016/j.rmed.2010.03.03320418083
   PubMed Web of Science ®Google Scholar
• TsiligianniI, MezziK, FucileS, et al. Response to indacaterol/glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE program. COPD. 2017;14(4):375–381. doi:10.1080/15412555.2017.132483728594587
   PubMedGoogle Scholar
• VestboJ, SorianoJB, AndersonJA, et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med. 2004;98(11):1045–1050. doi:10.1016/j.rmed.2004.03.01715526804
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SinghD, TsiligianniI, et al. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir Res. 2019;20(1):4. doi:10.1186/s12931-019-0972-730621717
   PubMed Web of Science ®Google Scholar
• PhamS, FergusonGT, KerwinE, GoodinT, WheelerA, BauerA. In vitro characterization of the eFlow Closed System nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162–169. doi:10.1089/jamp.2017.138429125918
   PubMed Web of Science ®Google Scholar
• LONHALA® MAGNAIR®. (Glycopyrrolate) Inhalation Solution [Package Insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2019.
   Google Scholar
• KerwinE, DonohueJF, GoodinT, TosielloR, WheelerA, FergusonGT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• LeidyNK, MurrayLT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013;10(3):393–398. doi:10.3109/15412555.2013.79542323713600
   PubMedGoogle Scholar
• JonesPW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
   PubMedGoogle Scholar
• LeidyNK, MurrayLT, MonzBU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15(1):124. doi:10.1186/s12931-014-0124-z25287629
   PubMed Web of Science ®Google Scholar
• FergusonGT, GoodinT, TosielloR, WheelerA, KerwinE. Long-term safety of glycopyrrolate/eFlow((R)) CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260. doi:10.1016/j.rmed.2017.08.02028919143
   PubMed Web of Science ®Google Scholar